Antimicrobial Resistance and Mortality in Carbapenem-Resistant Pseudomonas aeruginosa Infections in Southern Thailand

被引:0
作者
Chotimakorn, Parichart [1 ,2 ]
Pattharachayakul, Sutthiporn [3 ]
Lertsrisatit, Yongyut [3 ]
Santimaleeworagun, Wichai [4 ]
Tansakul, Pimpimon [5 ]
Yingkajorn, Mingkwan [6 ]
Chelae, Sureerat [6 ]
Pomwised, Rattanaruji [7 ]
Chukamnerd, Arnon [8 ]
Soontarach, Rosesathorn [8 ]
Chusri, Sarunyou [8 ]
机构
[1] Coll Pharmacotherapy Thailand, Nonthaburi 11000, Thailand
[2] Bhumibol Adulyadej Hosp, Dept Pharm, Bangkok 10220, Thailand
[3] Prince Songkla Univ, Fac Pharmaceut Sci, Dept Clin Pharm, Hat Yai 90110, Thailand
[4] Silpakorn Univ, Fac Pharm, Dept Pharm, Nakhon Pathom 73000, Thailand
[5] Prince Songkla Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Pharmaceut Bot, Hat Yai 90110, Thailand
[6] Prince Songkla Univ, Fac Med, Dept Pathol, Hat Yai 90110, Thailand
[7] Prince Songkla Univ, Fac Sci, Div Biol Sci, Hat Yai 90110, Thailand
[8] Prince Songkla Univ, Fac Med, Dept Internal Med, Div Infect Dis, Hat Yai 90110, Thailand
来源
ANTIBIOTICS-BASEL | 2025年 / 14卷 / 03期
关键词
carbapenem-resistant Pseudomonas aeruginosa; efflux pump; porin; beta-lactamase; mortality; risk factors; URINARY-TRACT-INFECTIONS; CEFTAZIDIME-AVIBACTAM; DOUBLE-BLIND; HOSPITALIZED-PATIENTS; PLUS METRONIDAZOLE; DISEASES SOCIETY; MEDICAL-CENTERS; UNITED-STATES; EFFLUX PUMPS; RISK-FACTORS;
D O I
10.3390/antibiotics14030322
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background/Objectives: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is an important pathogen associated with high mortality and treatment failure rates. We aimed to assess the susceptibility of CRPA to antipseudomonal agents, identify its resistance mechanisms, and evaluate clinical outcomes in a sample of CRPA isolates. Methods: This was an in vitro study of a clinical isolate of CRPA from hospitalized patients with CRPA infection and a retrospective observational study of these patients, who were diagnosed between 14 February 2021 and 10 August 2023 at Songklanagarind Hospital in Songkhla, Thailand. In vitro experiments were conducted to determine the minimum inhibitory concentrations (MICs) of the antipseudomonal agents using the broth microdilution method. Resistance mechanisms were assessed using the modified carbapenem inactivation method, combined disk tests, and quantitative real-time reverse transcription polymerase chain reaction. Results: A total of 140 CRPA isolates were analyzed. Both traditional and novel beta-lactams had high MICs. The most common resistance mechanism was the upregulation of the MexAB-OprM efflux pump (81.3%), followed by the downregulation of the OprD porin (48.9%) and metallo-beta-lactamase (MBL) production (45.0%), and the overexpression of blaAmpC (41.0%). The 30-day all-cause mortality rate was 30.5%. The risk factors associated with 30-day mortality included a Charlson Comorbidity Index of >= 5 (OR: 3.43; 95% CI: 1.07-10.99; p = 0.03), sepsis (OR: 10.62; 95% CI: 1.26-89.44; p = 0.03), and septic shock (OR: 4.39; 95% CI: 1.67-11.55; p < 0.01). In contrast, receiving active documented therapy was significantly associated with reduced mortality (OR: 0.17; 95% CI: 0.04-0.74; p = 0.01). Conclusions: This study revealed higher MIC values of all beta-lactams for CRPA, while colistin and amikacin remained effective. The resistance mechanisms included MexAB-OprM overexpression, OprD downregulation, MBL production, and blaAmpC overexpression, with a higher prevalence of MBL than in other regions of Thailand. High 30-day mortality was associated with comorbidities, sepsis, and septic shock, but active therapy reduced mortality.
引用
收藏
页数:18
相关论文
共 83 条
[1]  
Algun U, 2004, Indian J Med Microbiol, V22, P112
[2]  
[Anonymous], 2017, WHO publishes list of bacteria for which new antibiotics are urgently needed
[3]  
[Anonymous], 2021, Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2021
[4]  
[Anonymous], 2023, CDC/NHSN Surveillance Definitions for Specific Types of Infections
[5]  
[Anonymous], 2023, Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp, and other Aerobic Actinomycetes, V33rd
[6]   Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation [J].
Asuphon, O. ;
Montakantikul, P. ;
Houngsaitong, J. ;
Kiratisin, P. ;
Sonthisombat, P. .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 50 :23-29
[7]   Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study [J].
Babich, Tanya ;
Naucler, Pontus ;
Karlsson Valik, John ;
Giske, Christian G. ;
Benito, Natividad ;
Cardona, Ruben ;
Rivera, Alba ;
Pulcini, Celine ;
Fattah, Manal Abdel ;
Haquin, Justine ;
Macgowan, Alasdair ;
Grier, Sally ;
Gibbs, Julie ;
Chazan, Bibiana ;
Yanovskay, Anna ;
Ben Ami, Ronen ;
Landes, Michal ;
Nesher, Lior ;
Zaidman-Shimshovitz, Adi ;
McCarthy, Kate ;
Paterson, David L. ;
Tacconelli, Evelina ;
Buhl, Michael ;
Mauer, Susanna ;
Rodriguez-Bano, Jesus ;
Morales, Isabel ;
Oliver, Antonio ;
De Gopegui, Enrique Ruiz ;
Cano, Angela ;
Machuca, Isabel ;
Gozalo-Marguello, Monica ;
Martinez Martinez, Luis ;
Gonzalez-Barbera, Eva M. ;
Gomez Alfaro, Iris ;
Salavert, Miguel ;
Beovic, Bojana ;
Saje, Andreja ;
Mueller-Premru, Manica ;
Pagani, Leonardo ;
Vitrat, Virginie ;
Kofteridis, Diamantis ;
Zacharioudaki, Maria ;
Maraki, Sofia ;
Weissman, Yulia ;
Paul, Mical ;
Dickstein, Yaakov ;
Leibovici, Leonard ;
Yahav, Dafna .
CLINICAL INFECTIOUS DISEASES, 2020, 70 (11) :2270-2280
[8]   Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial [J].
Bassetti, Matteo ;
Echols, Roger ;
Matsunaga, Yuko ;
Ariyasu, Mari ;
Doi, Yohei ;
Ferrer, Ricard ;
Lodise, Thomas P. ;
Naas, Thierry ;
Niki, Yoshihito ;
Paterson, David L. ;
Portsmouth, Simon ;
Torre-Cisneros, Julian ;
Toyoizumi, Kiichiro ;
Wunderink, Richard G. ;
Nagata, Tsutae D. .
LANCET INFECTIOUS DISEASES, 2021, 21 (02) :226-240
[9]   Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections [J].
Bauer, Karri A. ;
West, Jessica E. ;
O'Brien, James M. ;
Goff, Debra A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (07) :2907-2912
[10]   GENERAL-GUIDELINES FOR THE CLINICAL-EVALUATION OF ANTIINFECTIVE DRUG PRODUCTS [J].
BEAM, TR ;
GILBERT, DN ;
KUNIN, CM .
CLINICAL INFECTIOUS DISEASES, 1992, 15 :S5-S32